An extensive search for autoantibodies to myelin basic protein in cerebrospinal fluid of non-multiple-sclerosis patients: Implications for the pathogenesis of multiple sclerosis

European Neurology

Volumn 42, Issue 2, 1999, Pages 95-104

  Warren, Kenneth G ^a   Catz, Ingrid ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Autoantibodies to myelin basic protein; Immunoglobulins; Multiple sclerosis

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G; MYELIN BASIC PROTEIN;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CEREBROSPINAL FLUID; DEMYELINATION; ENCEPHALOMYELITIS; FEMALE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; INFLAMMATORY DISEASE; LEUKODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; SPINAL CORD DISEASE; STROKE; SYSTEMIC DISEASE; WERNICKE KORSAKOFF SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CENTRAL NERVOUS SYSTEM DISEASES; CEREBROVASCULAR DISORDERS; CHILD; ENCEPHALOMYELITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; NEURODEGENERATIVE DISEASES; SCLEROSIS; SPINAL CORD DISEASES;

EID: 0032799799     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069418     Document Type: Article

References (48)

1. Carson JH, Barbarese E, Braun PE, McPherson TA: Components in multiple sclerosis cerebrospinal fluid that are detected by radioimmunoassay for myelin basic protein. Proc Natl Acad Sci USA 2978;75:1976-1978.
2. Panitch HS, Hooper CJ, Johnson KP: CSF antibody to myelin basic protein: Measurements in patients with multiple sclerosis and subacute sclerosing panencephalitis. Arch Neurol 1980;37:206-209.
3. Bernard CCA, Randell VB, Horvath LB, Carnegie PR, MacKay IR: Antibody to myelin basic protein in extracts of multiple sclerosis brain. Immunology 1981;43:447-457.
4. Brokstad KA, Page M, Nyland H, Haaheim LR: Autoantibodies to myelin basic protein are not present in the serum and CSF of MS patients. Acta Neurol Scand 1994;89:407-411.
5. Warren KG, Catz I: Relative frequency of autoantibodies to myelin basic protein and protcolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. J Neurol Sci 1994; 121:66-73.
6. Warren KG, Catz I, Johnson E, Mielke B: Antimyelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann Neurol 1994;35:280-289.
7. Warren KG, Catz I: Diagnostic value of cerebrospinal fluid anti-myelin basic protein in patients with multiple sclerosis. Ann Neurol 1986;20:20-25.
8. Warren KG, Catz I: A correlation between cerebrospinal tluid myelin basic protein and anti-myelin basic protein in multiple sclerosis patients. Ann Neurol 1987;21:183-189.
9. Söderström M, Link H, Xu Z, Fredriksson S: Optic neuritis and multiple sclerosis: Anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF. Neurology 1993;43:1215-1222.
10. Warren KG, Catz I: Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid. J Neuroimmunol 1992;39:81-90.
11. Warren KG, Catz I, Steinman L: Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: The minimal B cell epitope and a model of its features. Proc Natl Acad Sci USA 1995;92:11061-11065.
12. Wucherpfennig KW, Catz I, Hausmann S, Strominger J, Steinman L, Warren KG: Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. J Clin Invest 1997;100:1114-1122.
13. Trotter JL, Cross AH: Autoantibodies in demyelinating disease: in Cook SD (ed): Handbook of Multiple Sclerosis; New York, Dekker, 1996, pp 187-199.
14. Gorny MK, Wróblewska Z, Pleasure D, Miller S, Wajgt A, Koprowski H: CSF antibody to myelin basic protein and oligodendrocytes in multiple sclerosis and other neurological diseases. Acta Neurol Scand 1983;67:338-347.
15. Bashir RM, Whitaker JN: Molecular features of immunoreactive myelin basic protein in cerebrospinal fluid of persons with multiple sclerosis. Ann Neurol 1980;7:50-57.
16. Singh VK, Warren RP, Odell JD, Warren WL, Cole P: Antibodies to myelin basic protein in children with autistic behavior. Brain Behav Immunol 1993;7:97-103.
17. Kerlero de Rosbo N, Ben-Nun A: T cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycometer. J Autoimmun 1998;11:287-299.
18. Link H, Tibbling G: Principles of albumin and IgG analyses in neurological disorders. II. Evolution of IgG syntheses within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 1977;37:397-401.
19. Walsh MJ, Tourtelotte WW: The cerebrospinal fluid in multiple sclerosis: in Hallpike JF, Adams CMW, Tourtelotte WW (eds): Multiple Sclerosis. Baltimore, Williams and Williams, 1982, pp 275-358.
20. Deibler GE, Martenson RE, Kies MW: Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem 1972;2:139-165.
21. H4 germline segments in an acute multiple sclerosis brain. Ann Neurol 1998;43:236-243.
22. Wekerle H, Bradl M, Linington C, Kaab G, Kojima K: The shaping of the brain-specific T lymphocytes repertoire in the thymus. Immunol Rev 1996;149:231-243.
23. Garren H, Steinman L, Lock C: The specificity of the antibody response in multiple sclerosis. Ann Neurol 1998;43:4-5.
24. Hemmer B, Vergelli M, Tranquill L, Conlon P, Ling N, McFarland HF, Martin R: Human T cell response to myelin basic protein 83-99. Neurology 1997;49:1116-1126.
25. Warren K, Catz I: Neutralization of anti-myelin basic protein by cerebrospinal fluid of multiple sclerosis patients in clinical remission. J Neurol Sci 1988;88:185-194.
26. Warren KG, Catz I: A myelin basic protein antibody cascade in purified IgG from cercbrospinal fluid of multiple sclerosis patients. J Neurol Sci 1990;96:19-27.
27. Hohlfield R: Biotechnological agents for the immunotherapy of multiple sclerosis. Brain 1997;120:865-916.
28. Prineas JW, Connell F: The fine structure of chemically active multiple sclerosis plaques. Neurology 1978;28:68-75.
29. Esiri MM: Immunoglobulin-containing cells in multiple sclerosis plaques. Lancet 1977;ii:478.
30. Prineas JW: Pathology of multiple sclerosis; in Cook SD (ed): Handbook of Multiple Sclerosis, ed 2. New York, Dekker, 1996, vol 10, pp 22-255.
31. Lassman H, Suchanek G, Ozawa K: Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol 1994;94: S42-S46.
32. Ozawa K, Suchanek G, Breitschopf H, Bruck W, Budka H, Jellinger K, Lassmann H: Patterns of oligodendrocyte pathology in multiple sclerosis. Brain 1994;117:1311-1322.
33. Kabat EA, Glusman M, Knaub V: Quantitative estimation of albumin and gamma globulin in normal and pathologic cerebrospinal fluid by immunochemical methods. Am J Med 1948;4: 653-662.
34. Prineas JW, Wright RG: Macrophages, lymphocytes and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab Invest 1978;38:409-421.
35. Cooper MD, Kearney J, Scher I: B lymphocytes; in Paul WE (ed): Fundamental Immunology. New York, Raven Press, 1984, pp 43-55.
36. Nossal GJV: Life, death and the immune syslem. Sci Am 1998;269:53-62.
37. McAlpine D, Lumsden CE, Acheson ED (eds): Multiple Sclerosis: A Reappraisal, ed 2. Edinburgh, Churchill Livingstone, 1972.
38. Warren KG, Catz I: Cerebrospinal fluid autoantibodies to myelin basic protein in multiple sclerosis patients. Detection during first exacerbations and kinetics of acute relapses and subsequent convalescent phases. J Neurol Sci 1989;143-151.
39. Tyor WR: Fundamentals of immunology; in Rolak LA, Haraty Y (eds): Neuroimmunology for the Clinician. Boston, Butterworth-Heineman, 1997, pp 3-33.
40. Compston DA, Morgan BP, Oleesky D, Fifield R, Campbell AK: Cerebrospinal fluid Cq in demyelinating disease. Neurology 1986;36: 1503-1506.
41. Sanders ME, Koski CL, Robbins D, Shin ML, Frank MM, Joiner KA: Activated terminal complement in CSF of Guillian Barré Syndrome and multiple sclerosis. J Immunol 1986; 136:4456-4459.
42. Compston DA, Morgon BP, Campbell AK, Wilkins P, Cole G, Thomas ND, Jasani B: Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol 1989;15:307-316.
43. Compston A, Scolding N, Wren D, Noble M: The pathogenesis of demyelinating diseases: Insights from cell biology. Trends Neurosci 1991;14:175-182.
44. Harting HP, Archelos JJ, Zielasek J, Gold R, Koltzenburg M, Reiners KH, Toyka KV: Circulating adhesion molecules and inflammatory mediators in demyelination. Neurology 1995; 45(suppl 6):S22-S32.
45. Prineas JW, Graham JS: Multiple sclerosis: Capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 1981;10:149-158.
46. Prineas JW, Kwon EE, Sternberger NH, Lennon VA: The distribution of myelin associated glycoprotein and myelin basic protein in actively demyelinating multiple sclerosis lesions. J Neuroimmunol 1984;6:251-264.
47. Liblau R, Tisch R, Bercovici N, McDevitt HO: Systemic antigen in the treatment of T cell mediated autoimmune diseases. Immunol Today 1997;18:599-604.
48. 96 in chronic progressive multiple sclerosis. J Neurol Sci 1997; 152:31-38.